BioInvent International AB announced the appointment of Sylvie Ryckebusch as Chief Business Officer (CBO). Sylvie Ryckebusch is a pharmaceutical executive with over 20 years of experience in business development, alliance management, and corporate strategy. She has held senior leadership roles in both large multi-national corporations and biotech companies and has closed numerous biotech deals at all stages of a product life cycle.

She has supported BioInvent on a part time basis since 2019 and with the new position as CBO, she will join the company's executive management team. Prior to joining BioInvent, Sylvie has served in key positions at Serono, Merck KGaA, and Index Ventures as well as McKinsey and Company and the Harvard Business School. Sylvie holds a PhD in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland.